AndroGel (Testosterone Topical) and Erythrocytosis: The Biology of Why It Happens

What Erythrocytosis Actually Means in This Context

Erythrocytosis is an increase in circulating red blood cell mass. In clinical practice, clinicians use hematocrit (the percentage of blood volume occupied by red cells) or hemoglobin concentration as the proxy measurement. A hematocrit above 54% in adult men is the conventional threshold flagged by both the American Urological Association and the Endocrine Society as requiring intervention during testosterone therapy.

The term is sometimes used interchangeably with polycythemia, though polycythemia technically includes elevations in white cells and platelets as well. What AndroGel produces is a pure erythrocytosis, meaning only red cell mass goes up.

Why the Distinction from Injectable Testosterone Matters

The route of delivery shapes the magnitude of this effect. Intramuscular testosterone cypionate or enanthate generates sharp supraphysiologic peaks shortly after injection, then troughs before the next dose. Those peaks drive disproportionate EPO surges. A 2010 crossover study published in the Journal of Clinical Endocrinology and Metabolism found that transdermal testosterone produced significantly smaller hematocrit increases than intramuscular injections at equivalent replacement doses, with mean hematocrit rising approximately 1.5 percentage points with the gel versus 3.7 points with IM formulations over 12 months ([1]).

Steady-state serum testosterone from AndroGel 1.62% (applied daily) stays within or just above the normal physiologic range for most patients. That stability limits the amplitude of downstream erythropoietic signaling.

How Common Is It with AndroGel Specifically?

Published trial data for AndroGel 1% and 1.62% show polycythemia or elevated hematocrit in approximately 3 to 18% of patients, depending on dose and baseline characteristics. The prescribing information for AndroGel 1.62% (NDA 202763) reports polycythemia as an adverse reaction observed during clinical trials ([2]). The FDA's FAERS database contains hundreds of erythrocytosis reports linked to testosterone topical products, though reporting rates underestimate true incidence in the post-marketing setting.

The Step-by-Step Biology: How Testosterone Raises Red Cell Mass

Understanding this mechanism requires tracing a chain of events that begins in the hypothalamus and ends inside bone marrow. No single step is solely responsible. The biology involves at least four distinct pathways operating simultaneously.

Step 1: Testosterone Drives Renal EPO Secretion

Erythropoietin (EPO) is a glycoprotein hormone produced mainly by peritubular interstitial cells in the renal cortex. These cells contain oxygen-sensing machinery built around hypoxia-inducible factor 1-alpha (HIF-1α). When tissue oxygen delivery drops, HIF-1α stabilizes, translocates to the nucleus, and drives EPO gene transcription. Testosterone amplifies this same pathway even in the absence of true hypoxia.

Androgen receptors are expressed on renal EPO-producing cells. When testosterone binds those receptors, it increases HIF-1α transcriptional activity and directly upregulates EPO messenger RNA. A 1992 study by Eschbach and colleagues demonstrated that physiologic androgen concentrations increased EPO production in isolated kidney slices by 30 to 40% over controls ([3]). More recent work confirmed that testosterone increases EPO gene expression through an androgen response element located in the EPO promoter region ([4]).

The result: circulating EPO rises, and the bone marrow receives a stronger "make more red cells" signal.

Step 2: Direct Stimulation of Erythroid Progenitors

EPO works by binding to EPO receptors (EPOR) on burst-forming unit erythroid (BFU-E) and colony-forming unit erythroid (CFU-E) cells in bone marrow. Testosterone does not wait for the EPO loop to close before acting on marrow directly. Androgen receptors are expressed on erythroid progenitor cells. Testosterone binding increases the density of EPOR on those progenitors, making them more sensitive to whatever EPO is already circulating ([5]).

This dual action (more EPO being secreted plus more EPOR per progenitor cell) produces a multiplicative rather than simply additive push on red cell production. Even modest rises in serum testosterone can therefore produce measurable hematocrit changes over weeks to months.

Step 3: Hepcidin Suppression and Iron Mobilization

Red cell production is iron-limited. The body keeps a large fraction of iron sequestered in ferritin stores and bound to transferrin. Hepcidin, a 25-amino-acid peptide produced by the liver, is the master regulator of iron traffic. It binds ferroportin (the main iron-export channel on enterocytes and macrophages), causing its internalization and degradation. High hepcidin means less iron released into plasma.

Testosterone suppresses hepatic hepcidin production. This was documented in a 2013 study in Blood showing that testosterone administration in hypogonadal men lowered hepcidin levels by a mean of 35% within six weeks, which was followed by a rise in serum iron, transferrin saturation, and ultimately hemoglobin ([6]). The mechanism appears to involve testosterone-driven increases in erythroferrone, a hormone secreted by erythroid progenitors that itself suppresses hepcidin.

Less hepcidin means more ferroportin activity, more iron exported from gut enterocytes and macrophage stores, and more substrate available to support hemoglobin synthesis. This is a permissive mechanism: without adequate iron mobilization, the EPO signal alone could not sustain a significant hemoglobin rise.

Step 4: Effects on Red Cell Lifespan and Viscosity

Testosterone may also modestly reduce the normal rate of red cell destruction (eryptosis). Laboratory data suggest that androgen exposure alters red cell membrane lipid composition in ways that extend cellular survival. The clinical magnitude of this effect is likely small compared to the production-side mechanisms above, but it contributes to the net accumulation of circulating red cells over months of therapy ([7]).

The compounded result of all four mechanisms: more red cells are made, those cells have more EPO receptors to respond to, iron supply is unlocked to support hemoglobin synthesis, and each cell survives slightly longer. Hematocrit climbs.

Timeline: How Quickly Does Hematocrit Rise on AndroGel?

The erythropoietic response to testosterone is not instantaneous. EPO levels begin rising within days of starting therapy, but red cell turnover is slow. A single red blood cell survives roughly 120 days in circulation. The full expression of a new steady-state hematocrit therefore takes 3 to 4 months.

What Clinical Trials Show

In the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men aged 65 and older with low testosterone, hematocrit rose by a mean of 3.0 percentage points in the testosterone-treated group versus 0.5 points in placebo over 12 months. Polycythemia (hematocrit above 54%) occurred in 5.9% of testosterone-treated participants compared to 1.0% in the placebo group ([8]).

The TTrials used primarily topical testosterone gel, making that data directly applicable to AndroGel users. The absolute risk of crossing the 54% threshold was roughly 1 in 17 treated men over one year.

Factors That Accelerate or Amplify the Rise

Several patient-level variables predict who will develop clinically significant erythrocytosis:

• Baseline hematocrit above 48%: patients already near the upper end of normal have less buffer.
• Sleep apnea: nocturnal hypoxia independently activates HIF-1α, adding to testosterone's EPO stimulus. A 2018 analysis in JAMA Internal Medicine found that untreated obstructive sleep apnea doubled erythrocytosis risk in men on TRT ([9]).
• Chronic mountain or high-altitude residence: baseline hypoxia operates through the same HIF-1α pathway.
• Higher AndroGel dose (1.62% at 81 mg/day versus 40.5 mg/day): dose-response relationships appear consistent with the EPO-mediated mechanism.
• Age above 65: older men may have reduced renal clearance of EPO and slower erythroid progenitor cell turnover that paradoxically extends the window of accumulation.

Why the Topical Route Produces a Milder Effect Than Injections

This point deserves its own section because clinicians and patients sometimes assume that "testosterone is testosterone" regardless of delivery route. The erythropoietic biology makes that assumption wrong.

The Peak-Trough Hypothesis

HIF-1α stabilization and EPOR upregulation are concentration-dependent. With weekly or biweekly intramuscular injections, serum testosterone spikes to 1,000 to 1,800 ng/dL within 24 to 48 hours before falling to trough levels below 300 ng/dL. Those supraphysiologic peaks produce EPO pulses that the steady-state system cannot match. Daily AndroGel application produces a much flatter pharmacokinetic profile, with peak serum levels typically in the 400 to 700 ng/dL range for most dose regimens described in the NDA pharmacokinetics data ([2]).

Absorption Variability Matters

Transdermal testosterone absorption varies by 10 to 15-fold between individuals based on skin thickness, hydration, application site hair density, and showering behavior after application. Some patients who appear to be on a standard dose are actually absorbing substantially more or less than intended. Clinicians should interpret hematocrit data alongside actual measured serum testosterone, not just the nominal dose.

A simple three-zone clinical framework for managing erythrocytosis risk in AndroGel patients:

Zone 1 (Hematocrit 40 to 50%): Proceed with standard dosing. Recheck at 3 months and then annually.

Zone 2 (Hematocrit 50 to 54%): Reduce dose by one step (e.g., from 81 mg to 40.5 mg AndroGel 1.62%), recheck in 6 to 8 weeks, evaluate for sleep apnea.

Zone 3 (Hematocrit above 54%): Hold AndroGel, evaluate for secondary causes of erythrocytosis, consider therapeutic phlebotomy, and reassess whether to restart at a lower dose or switch to a different formulation.

What the Endocrine Society and AUA Guidelines Say

Both major guideline bodies directly address erythrocytosis as a known complication of testosterone therapy.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually. If the hematocrit is greater than 54%, stop therapy until hematocrit decreases to a safe level, evaluate the patient for hypoxia and sleep apnea, and reinitiate therapy at a reduced dose." ([10])

The AUA's 2018 Testosterone Deficiency Guidelines echo this threshold and specify that clinicians should evaluate for secondary erythrocytosis causes before attributing the finding to testosterone alone ([11]).

"Erythrocytosis is the most common adverse effect of testosterone replacement therapy that leads to dose adjustment or therapy discontinuation," wrote Bhasin and colleagues in their landmark review in the New England Journal of Medicine in 2019 ([12]).

These guidelines do not prohibit testosterone use in patients who develop erythrocytosis. They describe a managed approach: identify the degree of elevation, correct it, and adjust dosing to maintain benefit while limiting risk.

Risks Associated with Untreated Erythrocytosis on Testosterone

Elevated hematocrit increases blood viscosity. Whole blood viscosity rises exponentially, not linearly, as hematocrit climbs above 50%. At a hematocrit of 55%, viscosity is roughly double that at 45%. Higher viscosity increases the shear stress on vascular endothelium and slows microcirculatory flow, which may increase risk of venous thromboembolism and, in some models, arterial events.

What the Evidence Shows on Thrombosis Risk

A 2023 prespecified analysis of the TRAVERSE trial (N=5,204 men with hypogonadism and elevated cardiovascular risk) found that testosterone therapy was not associated with a statistically significant increase in major adverse cardiovascular events compared to placebo. However, the trial did report a higher incidence of pulmonary embolism in the testosterone group (0.9% vs. 0.5%, P<0.05) and a higher incidence of atrial fibrillation ([13]). The erythrocytosis-to-thrombosis causal chain was not directly tested in TRAVERSE, but the biological plausibility is well established in hematology literature on secondary polycythemia.

The practical takeaway: erythrocytosis is not a benign laboratory finding to watch indefinitely without action. The Endocrine Society's 54% threshold reflects the point at which viscosity-related risk outpaces the expected benefit of continued testosterone dosing without adjustment.

Managing Erythrocytosis: Practical Options

Dose Reduction

The most straightforward approach. Reducing AndroGel from 81 mg to 40.5 mg daily (for the 1.62% formulation) or from 10 g to 5 g daily (for the 1% formulation) lowers mean serum testosterone and attenuates EPO stimulus within days. Hematocrit typically begins falling within four to six weeks as senescent red cells are cleared without equivalent replacement.

Phlebotomy

Therapeutic phlebotomy (removing 450 to 500 mL of whole blood) acutely lowers hematocrit within hours. It is used when hematocrit is critically elevated (above 58 to 60%) or when a patient cannot tolerate dose interruption due to symptom burden. Phlebotomy depletes iron stores, which limits subsequent erythropoiesis even if testosterone levels remain unchanged. This is a useful short-term bridge but not a substitute for addressing the underlying testosterone dose.

Switching Delivery Route

If a patient tolerates and benefits from testosterone therapy but consistently develops erythrocytosis on any topical dose, switching to scrotal or nasal testosterone (Natesto), which produces lower systemic DHT and potentially more stable serum levels, may reduce erythropoietic drive. Evidence for this specifically in erythrocytosis management is limited and largely observational.

Addressing Sleep Apnea

Because untreated sleep apnea independently activates the HIF-1α/EPO axis, initiating CPAP therapy in a patient with concurrent sleep apnea and AndroGel-related erythrocytosis may produce meaningful hematocrit reductions without any change in testosterone dose. This approach is underused in practice.

Monitoring Protocol Recommended by HealthRX Clinical Team

Based on current AUA and Endocrine Society guidance, the HealthRX medical team uses the following monitoring schedule for patients starting AndroGel:

• Baseline: CBC with differential, serum testosterone (morning draw), and sleep apnea screening questionnaire (STOP-BANG).
• Week 12 (3 months): Hematocrit or hemoglobin, serum testosterone trough level.
• Month 6: Hematocrit, serum testosterone, and blood pressure.
• Annually thereafter: Full CBC, metabolic panel, and testosterone levels.

Any hematocrit above 50% at a scheduled check triggers a repeat measurement within four weeks to rule out dehydration artifact before adjusting therapy.